Based on the key indicators related to Viracta Therapeutics' liquidity, profitability, solvency, and operating efficiency, Viracta Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Viracta Therapeutics' Property Plant And Equipment Gross is fairly stable compared to the past year. Accumulated Other Comprehensive Income is likely to rise to 9,450 in 2024, whereas Total Assets are likely to drop slightly above 54.4 M in 2024. Key indicators impacting Viracta Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Viracta Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Viracta Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Viracta Therapeutics.
Net Income
(53.61 Million)
Viracta
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Cash Conversion Cycle
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Net Borrowings
Change To Operating Activities
Change To Netincome
Change To Liabilities
Investments
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Common Stock
Long Term Debt
Capital Surpluse
Property Plant Equipment
Other Assets
Net Tangible Assets
Retained Earnings Total Equity
Capital Lease Obligations
Net Invested Capital
Net Working Capital
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Interest Income
Net Income Applicable To Common Shares
Net Interest Income
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Viracta Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Viracta Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Viracta Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Viracta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Viracta Therapeutics. Check Viracta Therapeutics' Beneish M Score to see the likelihood of Viracta Therapeutics' management manipulating its earnings.
Viracta Therapeutics Stock Summary
Viracta Therapeutics competes with Vincerx Pharma, Rallybio Corp, Tenaya Therapeutics, Lyra Therapeutics, and Trevi Therapeutics. Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Viracta Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Viracta Therapeutics. It measures of how well Viracta is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Viracta Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Viracta had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Viracta Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Viracta Therapeutics's current stock value. Our valuation model uses many indicators to compare Viracta Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viracta Therapeutics competition to find correlations between indicators driving Viracta Therapeutics's intrinsic value. More Info.
Viracta Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Viracta Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viracta Therapeutics' earnings, one of the primary drivers of an investment's value.
Viracta Therapeutics Systematic Risk
Viracta Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Viracta Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Viracta Therapeutics correlated with the market. If Beta is less than 0 Viracta Therapeutics generally moves in the opposite direction as compared to the market. If Viracta Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Viracta Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Viracta Therapeutics is generally in the same direction as the market. If Beta > 1 Viracta Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Viracta Therapeutics Thematic Clasifications
Viracta Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Viracta Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Viracta Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Viracta Therapeutics growth as a starting point in their analysis.
Viracta Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Viracta Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Viracta Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Viracta Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Viracta Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Viracta Therapeutics's daily price indicators and compare them against related drivers.
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.